Metastatic Breast Cancer

SAN ANTONIO — Tinengotinib exhibited activity among heavily pretreated patients with hormone receptor-positive, HER2-negative breast cancer or those with triple-negative disease, according to study results.

Sarah L. Sammons, MD, was 7 when her mother was diagnosed with breast cancer.

Alana L. Welm, PhD, will receive the AACR Outstanding Investigator Award for Breast Cancer Research during this year’s San Antonio Breast Cancer Symposium.

The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.

Significant advancements have been made in the de novo metastatic breast cancer space, including novel agents targeting the HER2 protein and others that enhance anti-estrogen therapies.

Healio spoke with Eleonora Teplinsky, MD, about metastatic breast cancer and other challenging subtypes of breast cancer.

Patients with metastatic breast cancer treated with alpelisib as standard care had elevated blood glucose levels compared with those who received the drug as part of a clinical trial, according to data published in Cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about unmet needs that need to be addressed in metastatic breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about the difficulties of treating de novo metastatic breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about the latest research in metastatic breast cancer.